AEG 35156

Drug Profile

AEG 35156

Alternative Names: AEG 161; AEG35156; GEM 640

Latest Information Update: 29 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Aegera Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Liver cancer; Multiple sclerosis; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 12 Jul 2011 Aegera Therapeutics terminates phase I/II trial in Chronic lymphocytic leukaemia and B-cell lymphoma in USA and Canada NCT00768339)
  • 27 May 2011 Aegera Therapeutics has been acquired by Pharmascience
  • 19 Jul 2010 Efficacy and adverse events data from a phase I/II trial in liver cancer released by Aegera Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top